Drug Approval | May 01, 2022
USFDA approves Rinvoq as an oral treatment for ankylosing spondylitis
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
Ocular hypertension affects over 5% of all adults; the eye does not properly drain fluid, causing eye pressure to build up
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology
Divalproex Sodium Extended-Release tablets are indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, as monotherapy and adjunctive therapy and prophylaxis of migraine headaches
Clarithromycin tablets USP, 250 mg and 500 mg have an estimated market size of US $ 11 million for twelve months ending September 2021 according to IQVIA
In 2018 NATCO and Alvogen had filed an Abbreviated New Drug Application (ANDA) with PIV certification for the generic version of the product
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)